PRME vs. BCRX, IMCR, TECX, TARS, MESO, AUTL, VIR, CGEM, SANA, and IMTX
Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include BioCryst Pharmaceuticals (BCRX), Immunocore (IMCR), Tectonic Therapeutic (TECX), Tarsus Pharmaceuticals (TARS), Mesoblast (MESO), Autolus Therapeutics (AUTL), Vir Biotechnology (VIR), Cullinan Therapeutics (CGEM), Sana Biotechnology (SANA), and Immatics (IMTX). These companies are all part of the "biological products, except diagnostic" industry.
Prime Medicine (NYSE:PRME) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
Prime Medicine has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals received 465 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 66.53% of users gave BioCryst Pharmaceuticals an outperform vote while only 64.00% of users gave Prime Medicine an outperform vote.
Prime Medicine has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -38.18%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Prime Medicine's return on equity.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 24.3% of Prime Medicine shares are held by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Prime Medicine presently has a consensus target price of $14.11, indicating a potential upside of 302.03%. BioCryst Pharmaceuticals has a consensus target price of $14.17, indicating a potential upside of 86.90%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than BioCryst Pharmaceuticals.
In the previous week, Prime Medicine had 7 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 16 mentions for Prime Medicine and 9 mentions for BioCryst Pharmaceuticals. Prime Medicine's average media sentiment score of 0.53 beat BioCryst Pharmaceuticals' score of 0.49 indicating that Prime Medicine is being referred to more favorably in the media.
Prime Medicine has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.
Summary
Prime Medicine beats BioCryst Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Prime Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prime Medicine Competitors List
Related Companies and Tools
This page (NYSE:PRME) was last updated on 10/7/2024 by MarketBeat.com Staff
Free PRME Stock Alerts